Colorectal Cancer
Conditions
Keywords
colorectal cancer, 5-FU, Aflibercept, Oxaliplatin
Brief summary
This is a controlled, open-label, randomized phase- II trial (1:1 randomization) investigating 5-FU + aflibercept and 5-FU + oxaliplatin in elderly and frail elderly patients with mCRC scheduled to receive first line treatment.
Detailed description
The current trial seeks to evaluate a new treatment option for elderly / frail elderly patients with mCRC including 5-FU - better tolerated than capecitabine in the FOCUS2 study - in conjunction with aflibercept, a broad active anti-angiogenic drug within a randomized phase-II setting. Patients will be randomized using a 1:1 randomization between 5-FU / aflibercept and 5-FU / oxaliplatin using the oxaliplatin-based regimen established in FOCUS2 trial. Main goal is to estimate the 6-months PFS rate with 5-FU / Aflibercept and the safety of this regimen. The decision to use a randomized phase-II design using the FOCUS2- FOLFOX is based on two assumptions; (i) Bias can be better controlled by using a randomized phase-II design (ii) A clear standard regimen in frail elderly cannot be defined, but FOLFOX was superior to 5-FU alone in FOCUS2 and the patient population included in the FOCUS2 study represents the patient population scheduled to be included in the current trial. Provided the randomized phase-II study shows adequate efficacy of 5-FU / aflibercept and a tolerable safety profile, the study will be carried on to the phase-III part of the trial. Description of the terms and conditions to expand the current trial are not part of this protocol. Briefly, a potential phase-III study should aim at showing non-inferiority of 5-FU / aflibercept regarding 6-months PFS rate as primary endpoint. This would allow to include all patients from the phase-II part in the phase-III study in order to save time and patients.
Interventions
DRUGAflibercept + mLV5FU2
Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
DRUGmFOLFOX7
Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
Sponsors
STABIL - Statistische und Biometrische Lösungen
Trium Analysis Online GmbH
Sanofi
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. To enter this trial the oncologist has to confirm, that the patient was in his or her opinion not a candidate for standard full-dose combination therapy. Moreover, the oncologist has to state the reason for entering the trial (Advanced age alone versus both age and frailty). As an operational definition for frailty the G8 screening tool will be used upon inclusion of the patient in a standardized manner. Briefly, G8 is an established screening tool that includes seven items from the Mini Nutritional Assessment (MNA) and an age-related item (\<80, 80 to 85, or 85 years). The total score can range from 0 to 17. The result on the G8 is considered abnormal if the score is ≤14, indicating a geriatric risk profile. 2. Patients have to have histologically confirmed mCRC with unidimensionally measurable inoperable advanced or metastatic disease 3. ECOG performance status of 2 or better. 4. Life expectancy of 3 months or longer at enrolment 5. Patients \>70 years with no upper age limit 6. Previous adjuvant chemotherapy is allowed if completed more than 6 months before randomisation 7. Previous rectal (chemo)radiotherapy is allowed if completed more than 6 months before randomisation 8. Hematological status: * Neutrophils (ANC) ≥ 1.5 x 109/L * Platelets ≥ 100 x 109/L * Hemoglobin ≥ 9 g/dL 9. Adequate renal function: • Serum creatinine level ≤ 1.5 x upper limit normal (ULN) 10. Adequate liver function: * Serum bilirubin ≤ 1.5 x upper limit normal (ULN) * Alkaline phosphatase ≤ 2.5 x ULN (unless liver metastases are present, then \< 5 x ULN in that case) * AST and ALT \< 3 x ULN (unless liver metastases are present then \< 5 x ULN in that case) 11. Proteinuria \< 2+ (dipstick urinalysis) or ≤ 1 g/24hour 12. Signed and dated informed consent, and willing and able to comply with protocol requirements 13. Regular follow-up feasible 14. Male patients with a partner of childbearing potential must agree to use effective contraception (Pearl Index \< 1) during the course of the trial and at least 3 months after last administration of the study drug.
Exclusion criteria
1. Prior systemic chemotherapy for mCRC 2. Other concomitant or previous malignancy, except: * Adequately treated in-situ carcinoma of the uterine cervix * Basal or squamous cell carcinoma of the skin * Cancer in complete remission for \> 5 years 3. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 Days 4. History or evidence upon physical examination of CNS metastasis unless adequately treated (irradiation and no seizure with appropriate treatment) 5. Uncontrolled hypercalcemia 6. Pre-existing peripheral neuropathy (NCI grade ≥2) 7. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy), 8. Treatment with any other investigational medicinal product within 28 days prior to study entry. 9. Significant cardiovascular disease: * Cardiovascular accident or myocardial infarction or unstable angina ≤6 months before start of study treatment * Severe cardiac arrhythmia * New York Heart Association grade ≥2 congestive heart failure * Uncontrolled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy. * History of stroke or transient ischemic attack ≤6 months before start of study treatment * Coronary/peripheral artery bypass graft ≤6 months before start of study treatment. * Deep vein thrombosis or thromboembolic events ≤1 month before start of study treatment 10. Patients with known allergy to any excipient to study drugs, 11. Any of the following within 3 months prior to randomization: Grade 3-4 gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event. 12. Bowel obstruction. 13. Treatment with CYP3A4 inducers unless discontinued \> 7 days prior to randomization 14. Known dihydropyrimidine dehydrogenase (DPD) deficiency 15. Involvement in the planning and/or conduct of the study (applies to both Sanofi staff and/or staff of sponsor and study site) 16. Patient who might be dependent on the sponsor, site or the investigator 17. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG. 18. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \[§ 40 Abs. 1 S. 3 Nr. 3a AMG\].
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 6 months | Rate of patients free of progression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Adverse events (AE) | 7 months | AE's will be summarized by presenting the number and percentages of patients having any AE |
| Safety: Dose modification of study drug due to adverse events | 6 months | Dose modifications, including discontinuations, will be summarized by presenting the number and percentages of patients having any dose modification |
| Safety: Rate of treatment discontinuation due to toxicitiy | 6 months | Rate of treatment discontinuations during the study |
| Safety: Laboratory abnormalities | 6 months | Summary of lab abnormalities as assessed in the documentation |
| Efficacy: Response rates | 2 years | As measured by RECIST criteria v. 1.1 |
| Safety: Dose intensities of study medication | 6 months | As calculated over the whole treatment duration and summarized descriptively by summary statistics. |
| Efficacy: PFS | 2 years | PFS according to Kaplan-Meier |
| Patient reported outcomes (PRO): Quality of life | 6 months | Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT. |
| PRO: Geriatric assessment | 6 months | Geriatric assessment as measured by using G8, ADL and IADL |
| PRO: Overall treatment utility | 6 months | Overall treatment utility is evaluated according to the principles used in the FOCUS2 trial. Cf. Seymour et al. Geriatric oncol 2013. |
| Efficacy: Overall survival (OS) | 2 years | OS according to Kaplan-Meier |
Countries
Germany
Outcome results
None listed